FRR Shares (Makes you Realise)

Equity

Home/ Are You A Trader/ Market Info/ Company Profile/ Smart Quotes

COMPANY PROFILE

DIVI'S LABORATORIES LTD.

NSE : DIVISLABBSE : 532488ISIN CODE : INE361B01024Industry : Pharmaceuticals & DrugsHouse : Divis Labs

BSE9269.00219 (+2.42 %)

PREV CLOSE (Rs.) 9050.00

OPEN PRICE (Rs.) 9149.60

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 13021

TODAY'S LOW / HIGH (Rs.)9080.05 9269.75

52 WK LOW / HIGH (Rs.)5637.5 9148.05

NSE9239.00179 (+1.98 %)

PREV CLOSE( Rs. ) 9060.00

OPEN PRICE (Rs.) 9099.50

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 9239.00 (118)

VOLUME 773225

TODAY'S LOW / HIGH(Rs.) 9080.50 9270.00

52 WK LOW / HIGH (Rs.)5636.5 9150

More From Company Profile

Smart Quotes

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Trade Value (Rs. in Lacs)

1196.25

Dividend Yield(%)

0.32

TTM EPS (Rs.)

110.79

P/E Ratio

83.67

Book Value (Rs.)

663.06

Face Value (Rs.)

MCap (Rs. in Mn)

2460628.27

Price/Earning (TTM)

71.91

Price/Sales (TTM)

22.36

Price/Book (MRQ)

13.98

PAT Margin (%)

24.98

ROCE (%)

21.89

Incorporation Year : 12-10 1990

Management Info :

Ramesh BV Nimmagadda - Chairman Murali K Divi - Managing Director

Registered Office :

Address : 1-72 / 23 (P) / Divis / 303,Divi Towers, Cyber Hills,Gachibowli,
Hyderabad,
Telangana-500032

Phone : 040 66966300 / 400

Email : mail@divislabs.com

Website : www.divislabs.com

Registrars Details :

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)

Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad

Listing : BSE, NSE

NEWS

01Aug Divis Laboratories informs about outco
Further to letter dated July 20, 2026, Divis Laboratories has informed t..

31Jul Divi's Laboratories informs about ces
Divi's Laboratories has informed that L. Ramesh Babu, Vice President (Pr..

24Jul Divi's Laboratories informs about ear
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosur..

Financials

	QTR Jun 26	ANNUAL 26
Net Profit	8910	26070
Gross Profit	11650	34360
Operating Profit	13030	39940
Net Sales	29740	103880

Rs. in Millions

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Glenmark Pharma. (BSE)

2517.40 (2.50%)

M.Cap (Rs. in Cr)71047.24

Sanofi Cons. Health (BSE)

4213.65 (1.37%)

M.Cap (Rs. in Cr)9704.30

Kwality Pharma (BSE)

3310.25 (1.37%)

M.Cap (Rs. in Cr)3434.78

Haleos Labs (BSE)

1542.00 (2.97%)

M.Cap (Rs. in Cr)466.19

Shareholding Pattern

	PROMOTERS	51.88%
	MUTUAL FUNDS/UTI	13.87%
	NON-INSTITUTION	8.54%
	FI/BANKS/INSURANCE	4.49%
	GOVERNMENT	0%
	FII	0%

Mf Holding

Scheme Name

Hold(%)

ICICI Pru Nifty Pha...

10.94

Nippon India Nifty ...

10.92

HDFC Pharma and Hea...

10.06

Quant Healthcare Fu...

9.99

ITI Pharma & Health...

9.03

ICICI Pru Nifty Hea...

8.96

Aditya Birla SL Nif...

8.96

Attention Investors

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month, Issued in the interest of Investors.

Risk Disclosure on Derivatives | Smart ODR | Mandatory Display | KYC Validation Links

BSE / NSE SEBI Registration No. INZ000279232, Depository Participant SEBI Registration No. – IN DP CDSL 132-2015

Mutual funds - ARN No. 81648 , Investment Adviser SEBI Registration No. : INA000008668.

CLOSE X

Risk Disclosures On Derivatives

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22

DIVI'S LABORATORIES LTD.

Smart Quotes

Attention Investors

Download Client Registration Documents

Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do's & Don't's) in Vernacular Language :

Filing complaints on SCORESEasy & quick

Risk Disclosures On Derivatives